Tigilanol Tiglate: The Clinical Paradigm Shift and Case Selection

Tigilanol tiglate is a recently approved drug for the indication of intratumoral treatment of canine mast cell tumors. Treatment of canine mast cell tumors with tigilanol tiglate results in an expected local wound with variability in size and healing time dependent on several tumor and patient characteristics. The lecture will include a brief review of the background research on tigilanol tiglate and the mode of action which leads to tumor necrosis, wound formation, healing and the predictability of tigilanol tiglate in clinical trials. Numerous cases will be included to demonstrate the variability of tigilanol tiglate treatment wounds and their subsequent management with a general hands-off approach. We will review several cases that experienced adverse events during treatment and will examine their outcomes using “hindsight” to assess whether the case selection was appropriate or if a change in the case management may have resulted in a different outcome. The entire lecture will emphasize the paradigm shift in clinical management when treating with tigilanol tiglate.